Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 2Phase 2 1

Status

Completed 4Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 8

Sponsor

Cancer Type

Genitourinary 8Breast 1

Conditions

Multiple Myeloma 243Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Recurrence 35Burkitt Lymphoma 24Neoplasms 20Neoplasms, Plasma Cell 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Immunoglobulin Light-chain Amyloidosis 13Leukemia 12Lymphoma 10Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large B-Cell, Diffuse 9Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Smoldering Multiple Myeloma 5Nausea 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasm, Residual 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Amyloidosis 4

Interventions

enzalutamide 92Magnetic Resonance Spectroscopy 87Specimen Handling 66Prednisone 65Androgen Antagonists 59Abiraterone Acetate 59apalutamide 56Radiosurgery 53Radiotherapy 47Leuprolide 47darolutamide 46abiraterone 44Docetaxel 43Radiation 31Pluvicto 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Biopsy 30relugolix 28Surveys and Questionnaires 28pembrolizumab 26gallium 68 PSMA-11 26Standard of Care 26Triptorelin Pamoate 25Goserelin 25bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20X-Rays 19luprolide acetate gel depot 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Dexamethasone × 1 year × Clear all
NCT06136650 2026-05-27

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,314 enrolled
Genitourinary

Prostatic Neoplasms

NCT06104449 2026-04-27

MK-5684-005

Merck Sharp & Dohme LLC

Phase 1 Completed
7 enrolled
Genitourinary

Prostatic Neoplasms

NCT04147806 2026-04-03

PROSINT

Albert Einstein College of Medicine

Phase 1 Active not recruiting
31 enrolled
Genitourinary

Prostatic Neoplasms

NCT06136598 2026-03-19

MK-5684-001

Merck Sharp & Dohme LLC

Phase 1 Completed
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT06616597 2026-02-19

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
58 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02776436 2026-02-17

REDEX

Leiden University Medical Center

Phase 1 Completed
46 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Astellas Pharma Inc

Phase 1 Recruiting
174 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

Merck Sharp & Dohme LLC

Phase 3 Completed
1,030 enrolled 24 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡